Research Laboratory

The Laboratory Research Team:Specialist Biomedical Scientist Scott ElliottPost-doctoral Research Scientist Dr Sharon GlaysherResearch Associate Practitioner Lis Connell

Ian Gedge

Our Backgrounds

Translational Oncology Research LaboratoryTORC

Respiratory Trials – Scott Elliott

Translational Research Laboratory

Pathology

Clinical Pathology

• Blood Sciences• Cellular Pathology

(including Cancer Laboratory)

• Microbiology

F-Level Research lab

• Service Development and Translation

• Respiratory research service• Clinical trial service support• PHT Hosted/Led Laboratory

Research• Innovation

Research Lab Resources/capabilityProcessing- Centrifuges – blood spinning etc- General laboratory equipment- Liquid N2 (for “snap-freezing”)- Dry ice (frozen shipment)Storage- -80C and -20C freezer - Fridges- Long and short termScientific Capability- Cell Culture- Molecular Biology (PCR)- Protein assays/ ELISA’s- Microscopy- Mutation Analysis- Cytological analysis – e.g. phenotyping patients with inflammatory airways

diseasesGeneral- Postgraduate student project support and supervision- Collaborations and Grant writing - Support for PHT initiated laboratory studies

• Stratified Medicine• Biomarkers• Cancer• Long-term respiratory conditions• Innovation• Translation

Our Scientific Areas of interest

PHT Based Laboratory Studies- Past / Present and Future

Breast Sentinel Lymph Node Assay

(First trust to translate into clinical practice)

Thyroid Cancer- BRAF on FNA samples

(First trust to translate into prospective use)

Mesothelioma Biomarker Discovery

(Novel multi biomarker approach in progress)

Cardiology Biomarkers

(MD studies Ongoing)

Asthma Differential

Counts(Now used clinically)

Stratified Cancer Therapies

(Nurse Led PhD Programme, Future work)

Transcription Factors (BBSRC Grant)

SENSOR (e-Health)

Prostate Biomarkers(Br J Cancer. 2012)

Asthma Urine Dipstick Test

(Patent Pending)

Efficacy of Anti-Cancer Drugs

(>40 publications over 10 years)

Dendritic Cell Immunology

(European funding)

Ovarian Biomarker Discovery

(MTOC Study in progress)

Asthma Deaths

(PhD Research)

Flow Cytometry and SELDI-TOF(Ongoing Respiratory Studies)

HER2 Testing in Breast Cancer

(now used Clinically)

Predictive peptide“Typical” pattern

Cancer Biomarkers – What’s so special?

PICK ME, PICK ME !

Molecular Targeted Therapies in Ovarian Cancer;

identifying potential biomarkers and overcoming mechanisms of resistance

Assess Tumour Cell Drug Sensitivity

Biomarkers- Search for drug sensitivity prediction

Cell Based Assays

Gene Expression Mutations

Assess Tumour Cell Drug Sensitivity

bevacizamab Dasatinib

Gefitinib ZSTK474

Lapatinib ZSTK474

crizotinib Dasatinib

Gefitinib Linsitinib

Lapatinib Linsitinib

ZSTK474 Linsitinib

olaparib Gefitinib

olaparib Lapatinib

cabozantinib ZSTK474

cabozantinib Trametinib

ruxolitinib everolimus

dabrafenib trametinib

ruxolitinib Trametinib

Dovitinib Trametinib

MK-1775 olaparib

VEGF A BCR-ABL/SRC

EGFR PI3K

EGFR, HER2 PI3K

MET, ROS1 BCR-ABL/SRC

EGFR IGF1R/IR

EGFR, HER2 IGF1R/IR

PI3K IGF1R/IR

PARP EGFR

PARP EGFR, HER2

FLT3, MET, VEGFR PI3K

FLT3, MET, VEGFR MEK/MAPK/ERK

JAK1/2 mTOR

RAF MEK/MAPK/ERK

JAK1/2 MEK/MAPK/ERK

FGFR1/2/3 MEK/MAPK/ERK

WEE-1 PARP

Drug Combinations Target Combinations

Multiple Targets Better Results

EGFR inhibitors – Gefitinib & Erlotinib PI3K inhibitor – ZSTK474

Sensitive

Resistant

WALK TO VICTORY

Research maybe hard work, demand long hours and lots of repetition

But with the incredible extended collaborative team we have here at Portsmouth, there is always fun to be had